Thermo Fisher Scientific Stock Gains on Bullish Analyst Coverage
Thermo Fisher Scientific (TMO) shares ROSE over 2% Tuesday, outperforming the S&P 500's 0.6% decline, after William Blair analyst Matt Larew initiated coverage with an outperform rating. The healthcare giant's diversified portfolio and best-in-class services position it as a one-stop shop for biopharma clients, despite current softness in that segment.
Larew highlighted Thermo Fisher's competitive advantages and ability to capitalize on a sector recovery. The stock, which has underperformed peers year-to-date, may be oversold given its stronger-than-expected Q2 fundamentals. This bullish outlook contrasts with the broader market's risk-off sentiment.